Kalaris Therapeutics Inc
NASDAQ:KLRSBiotechnology
+$0.16 today
- Market cap
- $54.75M
- Beta
- 0.14
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$1.86
Volume 0.07M
Average 0.08M
KLRS Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Kalaris Therapeutics IncNASDAQ: KLRS
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets rises 6.5% from a year ago
Total assets stood at $109.81M at the end of Q1 FY2026, up 6.5% from a year earlier and down 9.8% from the prior quarter. Over 3 fiscal years it compounded at +214.9% a year.
Context
- Total assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +6.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 121.74M USD
- Year-over-year change
- +2.7%
- 4-year CAGR
- -19.3%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 121.74M | +2.7% |
| FY2024 | 2024-12-31 | 118.55M | +3456.7% |
| FY2023 | 2023-12-31 | 3.33M | -14.5% |
| FY2022 | 2022-12-31 | 3.9M | -98.6% |
| FY2021 | 2021-12-31 | 286.59M | — |
Total Assets vs competitors
How KLRS compares with its peers on the latest reported figures
- Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
- Its year-over-year change of +6.5% is the 3rd highest of 9, against a peer median of -30.7%.
- Over three fiscal years its annual growth of +214.9% compares with a peer median of -11.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Mar 2026 | $241.99M USD | -24.7% | -24.7% | |
| Mar 2026 | $225.63M USD | +176.3% | -0.9% | |
IMAImageneBio Inc | Mar 2026 | $136.68M USD | +4.5% | -3.9% |
KLRSKalaris Therapeutics Inc | Mar 2026 | $109.81M USD | +6.5% | +214.9% |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $105.96M USD | -44.6% | -0.5% |
| Mar 2026 | $102.12M USD | +32.3% | -23.7% | |
| Mar 2026 | $58.86M USD | -36.7% | +21.7% | |
| Dec 2025 | $56.08M USD | -44.6% | -31.4% | |
| Mar 2026 | €48.94M EUR | -43.7% | -18.6% | |
| Peer median (excluding KLRS) | — | -30.7% | -11.2% | |
Competitors are the stored peer set for KLRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 201.66M | 3.06M | 3.17M | 118.29M | 98.05M |
| Short-term Investments | 46.46M | 0 | 0 | 0 | 19.93M |
| Net Receivables | 50K | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 5.18M | 3K | 17K | 257K | 78K |
| Total Current Assets | 253.35M | 3.9M | 3.33M | 118.55M | 118.81M |
| Property, Plant & Equipment (Net) | 31.29M | 0 | 0 | 0 | 1.48M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 852K | 0 | 0 | 0 | 499K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.1M | 0 | 0 | 0 | 953K |
| Total Non-current Assets | 33.25M | 0 | 0 | 0 | 2.93M |
| Total Assets | 286.59M | 3.9M | 3.33M | 118.55M | 121.74M |
| Account Payables | 8.36M | 2.76M | 2.36M | 247K | 1.28M |
| Short-term Debt | 6.59M | 0 | 0 | 0 | 316K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 15.03M | 296K | 540K | 1.96M | 6.52M |
| Total Current Liabilities | 37.85M | 5.69M | 3.94M | 5.24M | 9.71M |
| Long-term Debt | 0 | 3.25M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 25.23M | 44.41M | 0 | 32.08M |
| Total Non-current Liabilities | 23.48M | 28.48M | 44.41M | 0 | 33.21M |
| Total Liabilities | 61.33M | 34.17M | 48.35M | 5.24M | 42.92M |
| Common Stock | 7K | 0 | 0 | 0 | 2K |
| Retained Earnings | (297.07M) | (32.7M) | (47.39M) | (714.96M) | (160M) |
| Accumulated OCI | (155K) | 0 | 0 | (135K) | 6K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 225.27M | (30.27M) | (45.02M) | 113.31M | 78.81M |
| Total Debt | 30.07M | 3.25M | 0 | 0 | 1.45M |
| Net Debt | (171.6M) | 194K | (3.17M) | (118.29M) | (96.61M) |
Kalaris Therapeutics Inc
NASDAQ:KLRS
Intrinsic Alpha fair value
Locked
Current Price
$2.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.